Today, we are excited to announce a major partnership with @GSK to deploy the latest Boltz models across GSK’s research organization!

Would Harvey Specter use Harvey? @GabrielMacht had to ask.

if a toddler puts a sticker on you, that’s a sign of great respect in their culture

CRISPR genetic medicines are often described as more “convenient” than chronic treatments like pills or injections. 𝗜 𝘁𝗵𝗶𝗻𝗸 𝘁𝗵𝗶𝘀 𝗺𝗶𝘀𝘀𝗲𝘀 𝘁𝗵𝗲 𝗽𝗼𝗶𝗻𝘁 𝗲𝗻𝘁𝗶𝗿𝗲𝗹𝘆. 𝗜𝘁 𝗶𝘀 𝗹𝗶𝗸𝗲 𝘀𝗮𝘆𝗶𝗻𝗴 𝗳𝗹𝘆𝗶𝗻𝗴 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗰𝗼𝘂𝗻𝘁𝗿𝘆 𝗶𝘀 𝗺𝗼𝗿𝗲 𝗰𝗼𝗻𝘃𝗲𝗻𝗶𝗲𝗻𝘁 𝘁𝗵𝗮𝗻 𝘄𝗮𝗹𝗸𝗶𝗻𝗴. 𝗧𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹𝗹𝘆 𝘁𝗿𝘂𝗲, 𝗯𝘂𝘁 𝘄𝗶𝗹𝗱𝗹𝘆 𝗶𝗻𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲. One is not just an easier version of the other. Flying makes the journey possible for everyone, while only a select few could ever hope to complete a cross-country trek. We see this same dynamic play out again and again in cardiovascular disease. The current standard of care asks patients to commit to chronic therapy for decades: daily pills, repeat injections, and continued persistence fails for most. 𝗜𝗻 𝗿𝗲𝗰𝗲𝗻𝘁 𝘀𝘁𝘂𝗱𝗶𝗲𝘀, 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟳𝟬% 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗲𝗿𝗲 𝗻𝗼 𝗹𝗼𝗻𝗴𝗲𝗿 𝘁𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗲𝗶𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗮𝗳𝘁𝗲𝗿 𝗼𝗻𝗹𝘆 𝗮 𝗳𝗲𝘄 𝘆𝗲𝗮𝗿𝘀. Against that backdrop, describing durable genetic medicines as simply more “convenient” does no one justice. The current chronic medication paradigm, our “sick-care” framework, simply does not work well enough for silent lifelong diseases such as CVD. 𝗪𝗲 𝗺𝘂𝘀𝘁 𝗯𝘂𝗶𝗹𝗱 𝘀𝗼𝗺𝗲𝘁𝗵𝗶𝗻𝗴 𝗯𝗲𝘁𝘁𝗲𝗿. The goal is not just fewer doses. The goal is a model of prevention that is practical for all and matched to how lifelong risk actually works. 𝗪𝗲 𝘀𝗵𝗼𝘂𝗹𝗱 𝗻𝗼𝘁 𝘀𝗲𝘁𝘁𝗹𝗲 𝗳𝗼𝗿 𝗺𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝘄𝗮𝗹𝗸 𝗲𝗮𝘀𝗶𝗲𝗿. 𝗪𝗲 𝗺𝘂𝘀𝘁 𝗯𝘂𝗶𝗹𝗱 𝘁𝗵𝗲 𝗮𝗶𝗿𝗽𝗹𝗮𝗻𝗲. I am incredibly proud that the California Institute for Regenerative Medicine is helping us make that vision a reality. Scribe recently announced that we have been awarded more than $25 million from CIRM to help advance STX-1200 for Lp(a) and STX-1400 for severely elevated triglycerides toward the clinic. This funding helps us move these programs from possibility to patients. 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗦𝗰𝗿𝗶𝗯𝗲 𝘁𝗲𝗮𝗺, 𝗮𝗻𝗱 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝘁𝗼 𝗖𝗜𝗥𝗠 𝗳𝗼𝗿 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗼𝘂𝗿 𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝘁𝗼 𝗯𝗿𝗶𝗻𝗴 𝗱𝘂𝗿𝗮𝗯𝗹𝗲 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝗰𝗮𝗿𝗱𝗶𝗼𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗱𝗶𝘀𝗲𝗮𝘀𝗲.

Today we're launching Intercept: a $500M philanthropic initiative to make respiratory infections, like the common cold and flu, a thing of the past. We treat respiratory infections as a minor nuisance, but that’s really not the case. Most of us will spend 5% of our lives (!) sick from these viruses, they kill 1M people a year, cost $600B annually in productivity, and periodically threaten civilization through pandemics. So, if they’re such a big problem, why haven’t we dealt with them yet? Last year we convened ~40 leading scientists, pharma R&D leaders, biotech investors, and regulatory experts to better understand that. We heard two main reasons: (1) First, it’s just technically very challenging: respiratory viruses represent hundreds of distinct, mutating strains across several families. Fortunately, recent breakthroughs make this newly possible. (2) Second is a lack of funding: broad-spectrum solutions have historically been underfunded, in part because they’re not a great fit for most philanthropic or commercial funding (and while COVID generated a burst of activity around preventing and understanding respiratory infections through an influx of new funding, that hasn't been sustained). We think that with enough focus and funding, this might be solvable. Intercept is a $500 million philanthropic initiative that will take advantage of new tools to catalyze the development and deployment of two types of products: broad-spectrum preventatives and air cleaning technologies. This problem is undoubtedly difficult. But it’s more tractable now than it’s ever been. We think we should give it our best shot. We’re enormously grateful to our anchor funders: @stripe, @AnthropicAI, @TheFluLab, @FoundationOAI and individuals from Jane Street. And, I’m very excited to be building this with @incredutility and the rest of the team.

After almost five meaningful years at the @IcahnMountSinai, I’ll be wrapping up my time here at the end of June and closing this chapter of my academic career. I’m deeply grateful to my colleagues, trainees, collaborators, and leaders at Mount Sinai for the opportunities to build programs together and push the science of neuroimmunology and care of inflammatory skin (and other) disease forward — it has been a privilege to grow alongside such a talented community. In July, I’ll be joining the Feinstein Institutes for Medical Research & @NorthwellHealth as the inaugural Chief Biotechnology Officer, focusing on building new bridges between discovery, clinical research, and biotech across the health system. I’m excited about the chance to help accelerate translational science at scale and to work with new partners across academia, industry, and venture. My lab will continue to focus on foundational science in neuroimmunology. More details soon. To everyone I’ve had the chance to work with so far — thank you. I’m looking forward to staying in touch, finding new ways to collaborate, and continuing to advance the field together from this new perch.

Medal Ceremony for the first OpenADMET competition complete with AI generated anthems. 1st Place: @inductive_bio 2nd: @Merck 3rd: @Merck_KGAA